| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | K2ZSF0992C |
Structure
| InChI Key | GMIZZEXBPRLVIV-SECBINFHSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C15H18BrN7 |
| Molecular Weight | 376.26 |
| AlogP | 1.94 |
| Hydrogen Bond Acceptor | 7.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 2.0 |
| Polar Surface Area | 86.06 |
| Molecular species | BASE |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 23.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Serine/threonine-protein kinase Chk1 inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
CAMK protein kinase group
CAMK protein kinase CAMK1 family
CAMK protein kinase CHK1 subfamily
|
- | 3 | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hodgkin Disease | 1 | D006689 | ClinicalTrials |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | D054198 | ClinicalTrials |
| Leukemia, Myeloid, Acute | 1 | D015470 | ClinicalTrials |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | D015464 | ClinicalTrials |
| Lymphoma, Non-Hodgkin | 1 | D008228 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL2386889 |
| DrugBank | DB11899 |
| EPA CompTox | DTXSID00237551 |
| FDA SRS | K2ZSF0992C |
| SureChEMBL | SCHEMBL2408669 |
| ZINC | ZINC000060328032 |
CONTENTS